Salt Lake City, Utah-based USANA Health Sciences yesterday announced financial results for its fiscal second quarter ended June 30, 2018.
Net sales were $301.5 million, compared with $257.1 million in the prior-year period, a 17.3 percent increase year-over-year.
Celavive, the company’s new skincare line, contributed approximately $7 million in incremental sales for the quarter. In markets where Celavive has launched, skin and personal care products accounted for 9.5 percent of overall sales in the second quarter of 2018, versus 5.7 percent a year ago. The company’s total number of active customers increased 5.3 percent year-over-year to 597,000.
“Our operating results for the second quarter exceeded our expectations and reflect the momentum we are seeing in most of our regions,” said CEO Kevin Guest. “This momentum helped us generate the highest quarterly revenue and earnings per share in the company’s history.”
Net sales in the Asia Pacific region increased by 21.2 percent to $241.6 million for the second quarter of 2018. Within Asia Pacific, net sales increased 22.8 percent in Greater China; increased 36.1 percent in North Asia; and increased 12.5 percent in the Southeast Asia Pacific region.
Net sales in the Americas and Europe region for the second quarter of 2018 increased by 3.7 percent to $59.9 million, and active Customers in this region declined 4.8 percent.
USANA is updating its outlook for 2018 to consolidated net sales between $1.17 and $1.20 billion; previously it was between $1.13 and $1.17 billion.
To view the full USANA Q2 2018 report, click here.